Business Context and Reporting Period
Company: NANOVIRICIDES, INC.
Filing Type: Form 8-K (Current Report)
Reporting Date: July 2, 2014
Event: Entry into a Material Definitive Agreement and creation of a direct financial obligation.
Key Financial Metrics and Transaction Details
This filing reports a specific financing transaction rather than periodic financial performance metrics (revenue, profit, cash flow, or margins are not disclosed in this document).
- Principal Amount: $5,000,000
- Instrument: 10% Coupon Series C Convertible Debenture
- Investor: Dr. Milton Boniuk (Board Member)
- Maturity Date: June 30, 2018
- Interest Rate: 10% per annum, payable quarterly
- Conversion Price: $5.25 per share of Common Stock
- Additional Compensation: 187,000 shares of restricted Series A Convertible Preferred Stock (9 votes per share)
- Transaction Costs: No placement agent fees or commissions paid.
Material Changes and Terms
The filing details the terms of a new debt instrument with specific redemption and conversion features:
- Redemption Terms: The company may prepay the debenture. If the stock price exceeds $5.25 at the time of redemption, the company must pay in 951,381 shares of Common Stock plus unpaid interest. If the stock price is below $5.25 or the holder elects cash, the company pays principal plus accrued interest and an additional 7% per annum penalty interest.
- Preferred Stock Rights: The 187,000 Series A shares are non-dividend bearing and non-convertible unless a "change of control" occurs (defined as shareholders owning 60% or less of a new entity), at which point they convert to 3.5 shares of new common stock.
- Regulatory Status: Securities were sold under Section 4(2) and Rule 506 exemptions to an accredited investor.
Guidance, Outlook, and Risks
Management Commentary: The filing confirms the transaction was conducted directly without intermediaries. No forward-looking guidance, revenue outlook, or strategic commentary is provided in this specific report.
Risks and Contingencies:
- Dilution Risk: Conversion of the debenture or redemption at a stock price above $5.25 will result in significant issuance of common stock.
- Change of Control: The Series A Preferred Stock carries specific conversion rights triggered by a change of control, which could impact ownership structure in a merger or acquisition.
- Liquidity Obligation: The company has a contractual obligation to pay quarterly interest and principal (or equivalent shares) by 2018.
Investor Verification Checklist
- Verify the company's current cash position to ensure it can meet quarterly 10% interest payments.
- Confirm the current trading price of Common Stock relative to the $5.25 conversion and redemption threshold.
- Review the total authorized share count to assess the dilution impact of the potential 951,381 redemption shares and 187,000 Series A shares.
- Check for any subsequent filings regarding the status of the Series A Preferred Stock or changes in the company's capital structure.